FR EN
MI COMMUNITY
Together, we pursue a simple goal: to better understand the alterations of energetic metabolism in pancreatic cancer cells

Alice CARRIER
AMU, IPC, CRCM

MI COMMUNITY
Our aim is simple: to position ourselves upstream of the diagnosis and to propose innovative treatments to patients

Emmanuelle CHARAFE-JAUFFRET
AMU, IPC, CRCM

MI COMMUNITY
Veracyte (formerly HaliodDx) is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.

Vincent FERT
Veracyte

MI COMMUNITY
Thanks to this unprecedented alliance of researchers, clinicians, technological platforms and industrials we should be able to quickly do much better

Vincent BARLOGIS
AP-HM

MI COMMUNITY
Unique cluster in the world exclusively dedicated to basic and applied immunology, MI results from an efficient territorial game between research, industry, and the institutional stakeholders in economy and innovation.

Jacques PFISTER
CCI Marseille Provence

MI COMMUNITY
A therapeutic revolution is happening.

Bertrand NADEL
CIML, Institut Carnot CALYM, Cancéropole PACA

Newsletter
Stay informed
Subscribe
MI COMMUNITY
Marseille Immunopole should allow us now to accelerate the development of therapeutic antibodies, the new drugs that are changing the course of cancer treatment.

Jean-Paul BORG
AMU, IPC, CRCM

MI COMMUNITY
“Projects like PIONeeR allow us to contribute to the understanding of resistance to immunotherapy while opening clinical research to patients in Corsica, who, until recently, had no choice other than to fly to Marseille or Paris for such opportunities.”

Stéphane PROVENT
Centre Hospitalier, Clinique Maymard, Bastia

MI COMMUNITY
“Histopathology is critical to establish a diagnosis based on microscopic tissue examination, but is also of great importance to medical research protocols such as The PIONeeR Project.”

Laurence BAGUR MISTRE
AP-HM

MI COMMUNITY
MI carries a strong voice for immunology research, freeing partners from their public or private sectors, breaking down disciplinary barriers and creating the essential conditions for acting together, quickly and sustainably

Emilie GARRIDO-PRADALIE
AP-HM

Update of The Pioneer Project : 422 patients in the biomarker program, 65 patients in the umbrella clinical trial Read more
MI COMMUNITY
Education is also one of the strategic components of the Marseille Immunopole project.

Françoise DIGNAT-GEORGE
AMU, AP-HM, C2VN

MI COMMUNITY
“Our immunotherapy antibodies are positioned at the crossroads of two immunology fields with high potential: the g9d2 T cells and a novel superfamily of immunomodulators, butyrophilins”

Pierre d’EPENOUX
Imcheck Therapeutics

MI COMMUNITY
Our study models help to identify new potential therapeutic targets in preclinical models of personalized medicine.

Michel AURRAND-LIONS
AMU, IPC, CRCM

MI COMMUNITY
MI-mAbs allows researchers to validate the therapeutic potential of their discovery and permits industrials to focus their efforts on the most promising drug candidate

Francois ROMAGNÉ
AMU, MI-mAbs